| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/06/2013 | WO2013129929A1 Methods for activating retrovirus in latent infected cells, and compounds for use therein |
| 09/06/2013 | WO2013129700A1 Methods and compositions for enhancement of vision performance |
| 09/06/2013 | WO2013128453A1 Regeneration of islet beta cells by hsp60 derived peptides |
| 09/06/2013 | WO2013128450A1 Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes |
| 09/06/2013 | WO2013128391A1 Synthetic polypeptides and uses thereof |
| 09/06/2013 | WO2013128381A1 Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection |
| 09/06/2013 | WO2013128288A1 Monomeric bacterial actin adp-ribosyltransferases as cancer chemotherapeutics |
| 09/06/2013 | WO2013128239A1 Use of engrailed for increasing dopamine synthesis by dopaminergic neurons |
| 09/06/2013 | WO2013128003A1 N-terminally modified oligopeptides and uses thereof |
| 09/06/2013 | WO2013127779A1 Glp-1 prodrugs |
| 09/06/2013 | WO2013100818A3 A biocomposite for regeneration of injured tissue and organs, a kit for making the biocomposite, a method of making the biocomposite and a method of treating inquiries. |
| 09/06/2013 | WO2013096899A3 Stable formulations for cns delivery of arylsulfatase a |
| 09/06/2013 | WO2012099886A8 Compositions and mehthods for modulating gamma-c-cytokine activity |
| 09/05/2013 | US20130231351 Sir2 regulation |
| 09/05/2013 | US20130231293 Compositions and methods for the therapy and diagnosis of inflammatory bowel disease |
| 09/05/2013 | US20130231292 Synergistic anti-proliferation activity of TAS-108 with mTOR inhibitors against cancer cells |
| 09/05/2013 | US20130231291 Fermented soya based mixture comprising isoflavones- aglicones, equol and lunasil, process for the preparation and uses thereof in food, medical and cosmetic fields |
| 09/05/2013 | US20130231290 Methods of diagnosing and treating neurodegenerative diseases |
| 09/05/2013 | US20130231288 Human placental collagen compositions, and methods of making and using the same |
| 09/05/2013 | US20130231286 Use of Prolactin Receptor Antagonist and Chemotherapeutic Drug for Treating Ovarian Cancer |
| 09/05/2013 | US20130231285 Methods for Treating Skin Aging and Scars |
| 09/05/2013 | US20130231284 Methods of treating cartilage defects |
| 09/05/2013 | US20130231282 Methods for administering hypoglycemic agents |
| 09/05/2013 | US20130231280 Novel Peptide Involved in Energy Homeostasis |
| 09/05/2013 | US20130231279 Oxytocin treatment to improve memory and modify blood glucose |
| 09/05/2013 | US20130231278 Peptides containing tryptophan |
| 09/05/2013 | US20130231277 Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders |
| 09/05/2013 | US20130231276 Combination Of An Aminoacyl-tRNA Synthetase Inhibitor With A Further Antibacterial Agent For Attenuating Multiple Drug Resistance |
| 09/05/2013 | US20130231275 Aminiothiazoles and their uses |
| 09/05/2013 | US20130230918 Novel collectin |
| 09/05/2013 | US20130230598 Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid |
| 09/05/2013 | US20130230593 Orally Dosed Pharmaceutical Compositions Comprising a Delivery Agent in Micronized Form |
| 09/05/2013 | US20130230588 Controlled release compositions |
| 09/05/2013 | US20130230581 Egfr antagonist for the treatment of heart disease |
| 09/05/2013 | US20130230580 Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration |
| 09/05/2013 | US20130230573 Collagen structures and method of fabricating the same |
| 09/05/2013 | US20130230547 Methods and compositions for prostate cancer immunotherapy |
| 09/05/2013 | US20130230546 Chimeric VEGF Peptides |
| 09/05/2013 | US20130230538 Method of treating a patient having an autoimmune disorder by administering baffr polypeptide |
| 09/05/2013 | US20130230524 Protein Involved in Ovarian Cancer |
| 09/05/2013 | US20130230520 Pharmaceutical composition for treating bone diseases which comprises protein comprising frizzled1, frizzled2 or frizzled7 extracellular cysteine-rich domain |
| 09/05/2013 | US20130230518 Methods for treating sjogrens syndrome by administering a soluble ctla4 molecule |
| 09/05/2013 | US20130230515 Myostatin binding agents |
| 09/05/2013 | US20130230514 Compositions of pd-1 antagonists and methods of use |
| 09/05/2013 | US20130230509 Agent for neuropathic pain |
| 09/05/2013 | US20130230506 Methods for increasing intracellular activity of hsp70 |
| 09/05/2013 | US20130230504 Peptide antagonists of vascular endothelial growth factor and methods of use thereof |
| 09/05/2013 | US20130230502 Methods of treating cancer using opiod retargeted endopepidases |
| 09/05/2013 | US20130230501 Cycloalkyl-Substituted Imidazole Derivative |
| 09/05/2013 | US20130230500 Botulinum Toxin for Smoking Cessation |
| 09/05/2013 | US20130230499 Cellular blood markers for early diagnosis of als and for als progression |
| 09/05/2013 | US20130230492 Genetic inhibition by double-stranded rna |
| 09/05/2013 | US20130230490 PEG-Interferon Lambda 1 Conjugates |
| 09/05/2013 | US20130230487 Immunomodulatory Methods and Systems for Treatment and/or Prevention of Hypertension |
| 09/05/2013 | US20130230486 Compositions and methods to induce targeted apoptosis |
| 09/05/2013 | US20130230485 Methods for Treating Patients Undergoing Multi-Cycle Chemotherapy |
| 09/05/2013 | US20130230472 Bonding tissues and cross-linking proteins with naphthalimide compounds |
| 09/05/2013 | US20130230455 Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases |
| 09/05/2013 | US20130230454 Therapeutic Angiogenesis for Treatment of the Spine and Other Tissues |
| 09/04/2013 | EP2634252A2 Method of expressing proteins with disulfide bridges |
| 09/04/2013 | EP2633866A2 Combination therapy |
| 09/04/2013 | EP2633865A1 Use of interleukin-22 in treating viral hepatitis |
| 09/04/2013 | EP2633864A1 Clip inhibitors and methods of modulating immune function |
| 09/04/2013 | EP2633863A2 Method of treatment of conditions by administration of streptolysin O |
| 09/04/2013 | EP2633860A1 Stabilized factor IX formulations containing trehalose |
| 09/04/2013 | EP2633317A1 Treatment of gastrointestinal inflammation and psoriasis a |
| 09/04/2013 | EP2633065A2 Assays and kits to determine galactocerebrosidase activity on solid support |
| 09/04/2013 | EP2632952A2 Anti-sod1 antibodies and uses thereof |
| 09/04/2013 | EP2632939A2 Cancer-targeting peptides and uses thereof in cancer treatment and diagnosis |
| 09/04/2013 | EP2632480A1 Non-natural gelatin-like proteins with enhanced functionality |
| 09/04/2013 | EP2632479A1 Fviii peptides for immune tolerance induction and immunodiagnostics |
| 09/04/2013 | EP2632478A2 Treating diabetes melitus using insulin injections administered with varying injection intervals |
| 09/04/2013 | EP2632477A2 Methods of treatment with natriuretic peptides |
| 09/04/2013 | EP2632476A2 Method of improving transplant function using soluble complement receptor type i (scr1) |
| 09/04/2013 | EP2632446A1 Treatment for dupuytren's disease |
| 09/04/2013 | EP2632444A1 TREATMENT OF MeCP2-ASSOCIATED DISORDERS |
| 09/04/2013 | EP2632434A1 Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| 09/04/2013 | EP2632433A2 Liquid formulations of long acting interferon alpha conjugate |
| 09/04/2013 | EP1680443B1 Stabilized alpha helical peptides and uses thereof |
| 09/04/2013 | CN1980951B 抗微生物多肽 Antimicrobial peptides |
| 09/04/2013 | CN1622995B Receptor nucleic acids and polypeptides |
| 09/04/2013 | CN1578670B Use of lactalapoprotein in prevention and treatment of microbial or virus infection |
| 09/04/2013 | CN103282498A Methods and vectors for cell immortalisation |
| 09/04/2013 | CN103282494A C18orf54 peptides and vaccines including the same |
| 09/04/2013 | CN103282380A Erythrocyte-binding therapeutics |
| 09/04/2013 | CN103282379A Nd2 peptides and methods of treating neurological disease |
| 09/04/2013 | CN103282374A Methods and compositions for treating neurodegenerative disorders and alzheimer's disease and improving normal memory |
| 09/04/2013 | CN103282046A Methods and compositions for CNS delivery of arylsulfatase A |
| 09/04/2013 | CN103282045A Aqueous factor VIII solution |
| 09/04/2013 | CN103282044A Nanoemulsion-type ophthalmic composition |
| 09/04/2013 | CN103282043A Lissencephaly therapeutic agent |
| 09/04/2013 | CN103282042A Stabilization of immunoglobulins through aqueous formulation with histidine at weak acidic to neutral ph |
| 09/04/2013 | CN103282037A Combination therapy with an antitumor alkaloid |
| 09/04/2013 | CN103282030A Pharmaceutical composition, methods for treating and uses thereof |
| 09/04/2013 | CN103282022A Pharmaceutical compositions |
| 09/04/2013 | CN103275980A Antibodies, fusion protein and composition |
| 09/04/2013 | CN103275221A Human antibodies that bind human tnf alpha |
| 09/04/2013 | CN103275214A Gene engineering preparation and identification method for shrimp serine protease inhibitor |
| 09/04/2013 | CN103275190A Small molecular polypeptide ZY13 and application thereof |
| 09/04/2013 | CN103275187A Analgesic peptide FI as well as genes and application thereof |